Monoclonal antibodies in the treatment of advanced colorectal cancer

Capdevila, Jaume; Saura, Cristina; Macarulla, Teresa; Casado, Esther; Ramos, Francisco Javier; Tabernero, Josep

doi:10.1016/j.ejso.2007.09.025

Cited by 15 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The challenge for the near future is to identify biomarkers that are capable of predicting and targeting eligible patients for anti‐EGFR antibody treatment on a one‐to‐one scale. On the basis of reported trials and current debate [70], complex efforts are needed that take into consideration not only the mechanistic effect of blocking EGFR, but also the further exploiting of mAb effects on the immune system. Clearly, this is no simple task and, although there is now an impressive quantity of data in the field, we are still far from having a thorough understanding of the scenario as a whole.…”

Section: Resultsmentioning

confidence: 99%

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

Martinelli¹,

Palma

Orditura³

et al. 2009

Clinical and Experimental Immunology

302

210

View full text Add to dashboard Cite

SummaryThe epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor involved in the proliferation and survival of cancer cells. EGFR is the first molecular target against which monoclonal antibodies (mAb) have been developed for cancer therapy. Here we review the mechanisms underlying the effects of EGFR-specific mAb in cancer therapy. The efficacy of EGFR-specific mAb in cancer occurs thanks to inhibition of EGFRgenerated signalling; furthermore, the effects of antibodies on the immune system seem to play an important role in determining the overall anti-tumour response. In this review, attention is focused on cetuximab and panitumumab, two mAb introduced recently into clinical practice for treatment of metastatic colorectal and head and neck cancer which target the external part of EGFR.

show abstract

Section: Resultsmentioning

confidence: 99%

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

Martinelli¹,

Palma

Orditura³

et al. 2009

Clinical and Experimental Immunology

302

210

View full text Add to dashboard Cite

show abstract

“…9 10 In the context of an exponential increase in economic treatment costs, contributed by targeted therapy, the identification of a reliable, non-invasive, feasible and not costly predictive factor that would allow the selection of patients/tumours more likely to benefit from treatment and spare those who would not from additional toxicity is urgent. 3 19 …”

Section: Discussionmentioning

confidence: 99%

Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer

et al. 2016

View full text Add to dashboard Cite

BackgroundBevacizumab has become standard of care as first-line treatment of metastatic colorectal cancer (mCRC), after proving increased response rates and improvement in survival outcomes. Hypertension (HTN) is a common complication of the treatment with bevacizumab and, owing to its close relation with antiangiogenic mechanism, may represent a clinical biomarker to predict the efficacy of the treatment. The aim of this study was to retrospectively evaluate if HTN grades 2 to 3 were correlated with response to treatment with bevacizumab in first line, as well as with improved progression-free survival (PFS) and overall survival (OS), in a series of patients with mCRC.MethodsRetrospective evaluation of clinical records of patients with histologically proven mCRC, treated with bevacizumab as first-line treatment, between January 2008 and December 2013.Results79 patients were evaluated. 51.9% of patients developed HTN G2-G3 during chemotherapy-bevacizumab treatment. In the group of patients who developed bevacizumab-related HTN, 73.2% showed response to treatment (complete response (CR)+ partial response (PR)) and 97.6% achieved disease control (CR, PR or stable disease) compared to 18.4% of patients with response and 63.2% with disease control in the group that did not (OR 12.08; 95% CI 4.13 to 35.29; p<0.001 responders vs non-responders; OR 20.8; 95% CI 2.56 to 168.91; p 0.005 controlled vs non controlled disease). The median OS was 28 months (22.7–33.3). Significant statistical difference was obtained in PFS between the two groups (p<0.001). In the group that developed bevacizumab-related HTN, the median OS was 33 months (25.7–40.3), and in the group that did not, it was 21 months (16.5–25.5) with no significant statistical difference between the two groups (p 0.114).ConclusionsIn this subset of patients, HTN G2-3 was predictive of response to treatment with bevacizumab and of PFS but not of OS.

show abstract

“…Based on the Bowel Oncology With Cetuximab Antibody (BOND) study, cetuximab (Erbitux, ImClone Systems, Inc., New York), an anti-epithelial growth factor receptor (EGFR) mAb, was approved for treatment of patients with metastatic disease expressing EGFR refractory to irinotecan-based therapy. Panitumumab (Vectibix, Amgen, Thousand Oaks, CA) is another anti-EGFR mAb approved for therapy in those patients refractory to other chemotherapeutics [9]. While no survival benefit has been shown with mAbs as monotherapy, use is based on the advantages of mAbs in combination with other chemotherapy regimens.…”

Section: Alternative Available Therapies For Hepatic Metastasesmentioning

confidence: 99%

Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy

Kelly

Wong²,

Fong

2008

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Background Patients with hepatic malignancy have a dismal prognosis with standard therapies. NV1020 is an oncolytic herpes simplex virus that has potential to be a safe and effective therapeutic agent for this disease. Objective We set out to discuss the development of NV1020 as an oncolytic agent and explore the potential role of this particular virus in the setting of human hepatic cancer. Methods The scope of this review includes an overview of preclinical experience with NV1020, as well as an examination of current standard and developing therapies for liver cancer. The primary focus, however, is on the safety and potential clinical efficacy of NV1020 against hepatic malignancy. Results/conclusion We have found that NV1020 is a safe, novel therapeutic agent for treatment of refractory hepatic malignancy.

show abstract

Monoclonal antibodies in the treatment of advanced colorectal cancer

Cited by 15 publications

References 27 publications

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer

Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy

Contact Info

Product

Resources

About